Predictors of Emergency Department Attendance Following Ureterorenoscopy for Urolithiasis
Publication date: 2019Source: European Urology Supplements, Volume 18, Issue 5Author(s): E. Maccraith, J. O’Kelly, J. Ryan, J. Forde, I. Cheema, L. McLornan, N. Davis
The deficiency of vitamin D receptor (VDR) or its ligand, vitamin D3, is linked to the development of renal diseases. The TaqI (rs731236) and ApaI (rs7975232) polymorphisms of VDR gene are widely studied for t...
AbstractTo compare outcomes of a single middle calyx access (MCA) with a single upper or lower calyceal access in mini-PCNL. From May 2015 through August 2018, patients ’ files who underwent a single renal access mini-PCNL were retrospectively reviewed. All patients underwent fluoroscopic-guided access (16–20 F) in the prone position. They were categorized into group 1 (MCA) and group 2 (either upper or lower calyceal access). Compared preoperative items includ ed stone location, size, number and complexity (according to Guy’s score). The compared outcome parameters were complication and stone-free rates....
We report a large mobile bladder calculus with intense 99mTc-MDP uptake demonstrated on both whole-body bone scintigraphy and SPECT/CT images in a patient with complicated chronic history of urolithiasis and urinary tract infection. Bone tracer uptake in bladder calculus is a rare phenomenon and might be related to the composition and matrix of calculus, direct exposure to excreted radiotracer, and bacterial colonization on the surface of calculus.
We describe the phenotype of the Prodh2 knock out mouse model and show that the lack of HYPDH in PH mouse models results in lower levels of urinary oxalate excretion, consistent with our previous metabolic tracer and siRNA-based knockdown studies. The double knockout mouse, Grhpr KO (PH2 model) and Prodh2 KO, prevented calcium-oxalate crystal deposition in the kidney, when placed on a 1% Hyp diet. These observations support the use of the Grhpr KO mice to screen HYPDH inhibitors in vivo. Altogether these data support HYPDH as an attractive therapeutic target for PH2 and PH3 patients.Graphical abstract
Publication date: Available online 28 November 2019Source: Life SciencesAuthor(s): Yadong Liu, Song Chen, Jiannan Liu, Yinshan Jin, Shiliang Yu, Ruihua AnAbstractAimsTelmisartan (TLM), a highly selective angiotensin II type 1 receptor blocker (ARB) and partial PPAR-γ agonist, has versatile beneficial effects against oxidative stress, apoptosis, inflammatory responses and epithelial-mesenchymal transition (EMT). However, its underlying mechanism of inhibiting oxalate and calcium oxalate (CaOx) crystal-induced EMT by activating the PPAR-γ pathway remains unclear.Main methodsCCK-8 assays were used to evaluate the ...
ConclusionsIn line with studies in hypercortisolic state, even moderately high cortisol levels in healthy children, still within the physiological range, may negatively impact on the kidney ’s citrate excretion. Besides, a higher 11β-HSD2 activity, favoring cortisol inactivation, is paralleled by an increased citrate excretion.
ConclusionOur analysis showed that both procedures are safe for treatment of 10 –20 mm lower pole renal stones with similar complication rates, operative times, fluoroscopy times and length of hospital stay, but mini-PCNL was significantly superior in effectiveness with a higher success rate. Based on these results, mini-PCNL may be included in the guidelines as a safe and e ffective alternative treatment for 10–20 mm lower pole stones.
The history of urolithiasis on Earth began during the stone age (Mesolithic period) with the oldest stone identified (8,500 BCE) in Sicily within the bladder of a cave-dwelling woman.1 The history of stone disease has continued throughout human evolution with calculi being found in both the kidney and the bladder in ancient Homo sapiens.2 Hippocrates (460-370 BCE) recognized stone disease in society and included within the current Hippocratic oath, “I shall not cut for stone,” thus illustrating that urolithiasis is genuinely an ancient disease.
(The Academy of Medicine, Engineering&Science of Texas) Changing the future of Alzheimer's Disease. Utilizing crystals to produce drugs for kidney stones and malaria. Understanding previously unobserved functions of our universe. And pioneering the evolution of wound care. These are the discoveries by Texas' rising stars in research being honored with the 2020 Edith and Peter O'Donnell Awards by TAMEST.